Paragon Capital Management LLC Invests $54,000 in CannTrust Holdings Inc (CTST) Stock

Paragon Capital Management LLC purchased a new position in CannTrust Holdings Inc (NYSE:CTST) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 7,000 shares of the company’s stock, valued at approximately $54,000.

A number of other institutional investors have also modified their holdings of the business. Virtu Financial LLC bought a new stake in CannTrust in the first quarter worth about $618,000. Legacy Advisors LLC bought a new stake in CannTrust in the first quarter worth about $1,555,000. Finally, Davis Rea LTD. bought a new stake in CannTrust in the first quarter worth about $3,846,000. Hedge funds and other institutional investors own 0.08% of the company’s stock.

NYSE CTST traded down C$0.30 on Monday, hitting C$6.87. 1,388,522 shares of the company were exchanged, compared to its average volume of 1,167,752. The company has a current ratio of 7.65, a quick ratio of 5.54 and a debt-to-equity ratio of 0.06. The company has a market cap of $729.97 million, a PE ratio of -62.45 and a beta of 4.40. CannTrust Holdings Inc has a twelve month low of C$4.35 and a twelve month high of C$11.97.

CannTrust (NYSE:CTST) last posted its quarterly earnings data on Thursday, March 28th. The company reported C($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of C($0.04) by C($0.16). CannTrust had a negative return on equity of 7.34% and a negative net margin of 28.09%. The company had revenue of C$16.20 million for the quarter, compared to analyst estimates of C$20.99 million. The business’s revenue was up 131.4% on a year-over-year basis. Research analysts forecast that CannTrust Holdings Inc will post 0.03 EPS for the current fiscal year.

Several research firms have issued reports on CTST. Bloom Burton restated an “accumulate” rating on shares of CannTrust in a report on Friday, March 29th. Zacks Investment Research upgraded CannTrust from a “hold” rating to a “buy” rating and set a $9.00 price objective on the stock in a report on Tuesday, April 2nd.

ILLEGAL ACTIVITY WARNING: This report was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at

About CannTrust

CannTrust Holdings Inc produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital.

Recommended Story: How interest rates affect municipal bond prices

Want to see what other hedge funds are holding CTST? Visit to get the latest 13F filings and insider trades for CannTrust Holdings Inc (NYSE:CTST).

Receive News & Ratings for CannTrust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CannTrust and related companies with's FREE daily email newsletter.